PHGE (biomx.com) רווח נקי למניה (EPS TTM)

The rolling annual earnings per share of BiomX Inc. reflects a trend where the metric has reached the level of -217.47. BiomX Inc. robotic systems are accelerating bacteriophage discovery by replacing manual analysis. Drug production has been delegated to external CDMO facilities to minimize technical risks. However, the absence of commercial products leaves the business dependent on grants and legacy investments, as operating cash flow has not yet been established.

Investors in BiomX Inc. (PHGE) must reconcile the company's market value with its actual performance. This metric measures the aggregate net income over a trailing twelve-month period distributed per share. By analyzing the trend of the fundamental TTM earnings per share, investors can filter out short-term reporting volatility. For a bacteriophage developer facing deficient hospital demand, this metric reflects the pace of the transition toward monetization. Negative or increasing values here determine the investment payback horizon.